Summary
Latest filing:
Akintunde Olatokumbo Bello files SEC Form 4 reports at Xilio Therapeutics, Inc. (XLO). 1 SEC Form 4 filing on record, dated 12 June 2026.
Trading pattern
InsiderAlpha's records for Akintunde Olatokumbo Bello go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Akintunde Olatokumbo Bello files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GILEAD SCIENCES, INC. - $2.00M in XLO purchases and sales in the last 12 months
- James Samuel Shannon - $44K in XLO purchases and sales in the last 12 months
- Christopher James Frankenfield - $5K in XLO purchases and sales in the last 12 months
- Kevin M. Brennan - $1K in XLO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Akintunde Olatokumbo Bello?
Akintunde Olatokumbo Bello is a corporate insider of Xilio Therapeutics, Inc. (XLO). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Akintunde Olatokumbo Bello last file a Form 4?
The only primary Form 4 on record is dated 12 June 2026.